Latest Licensing News

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Triton Minerals has secured exploration license approval and will begin initial field works, including drilling, at its Aucu Gold-Copper Project in Mozambique starting October 2025. Early results are expected by December, setting the stage for further exploration next year.

Wellnex Life has secured a significant opening order from global partner Haleon for its Liquid Paracetamol and Ibuprofen softgel products in the UAE, marking the fourth national market in Haleon's distribution network. This milestone supports Wellnex's revenue forecasts for 2025 and underscores its strategic focus on innovative healthcare products.

Kincora Copper Limited has regained 100% ownership of its Mongolian copper-gold assets after Orbminco Limited's withdrawal, positioning itself to advance exploration and development at the promising Bronze Fox project.

X2M Connect has secured a significant contract to digitise water meters for 6,750 Seoul households, marking a key step in the city's ambitious A$240 million smart metering initiative.

ADX Energy has secured a pivotal court ruling that allows it to resume drilling and testing at its Welchau-1 well in Austria, overcoming environmental objections and strengthening its exploration prospects.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

Echo IQ has completed its presentation to the CPT Editorial Panel for a Category III CPT code for EchoSolv AS, with a decision expected from the American Medical Association in the coming weeks. Meanwhile, the company is advancing US deployments and FDA clearance efforts.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.